Pasar al contenido principal

AGENTES QUIMIOTERAPEUTICOS FRENTE A PATOGENOS AMPLIAMENTE DISEMINADOS (VIH Y LEISHMANIA): EXPLORANDO NUEVAS DIANAS Y/O NUEVOS MECANSIMOS DE INHIBICION

SAF2009-13914-C02-02

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2009
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD DE ALCALA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Mechanistic insight into the reaction catalysed by bacterial type II dehydroquinases

  • Coderch, Claire
  • Lence Quintana, Emilio José
  • Peón López, Antonio
  • Lamb, Heather
  • Hawkins, Alastair R.
  • Gago, Federico
  • González Bello, Concepción
DHQ2 (type II dehydroquinase), which is an essential enzyme in Helicobacter pylori and Mycobacterium tuberculosis and does not have any counterpart in humans, is recognized to be an attractive target for the development of new antibacterial agents. Computational and biochemical studies that help understand in atomic detail the catalytic mechanism of these bacterial enzymes are reported in the present paper. A previously unknown key role of certain conserved residues of these enzymes, as well as the structural changes responsible for triggering the release of the product from the active site, were identified. Asp89*/Asp88* from a neighbouring enzyme subunit proved to be the residue responsible for the deprotonation of the essential tyrosine to afford the catalytic tyrosinate, which triggers the enzymatic process. The essentiality of this residue is supported by results from site-directed mutagenesis. For H. pylori DHQ2, this reaction takes place through the assistance of a water molecule, whereas for M. tuberculosis DHQ2, the tyrosine is directly deprotonated by the aspartate residue. The participation of a water molecule in this deprotonation reaction is supported by solvent isotope effects and proton inventory studies. MD simulation studies provide details of the required motions for the catalytic turnover, which provides a complete overview of the catalytic cycle. The product is expelled from the active site by the essential arginine residue and after a large conformational change of a loop containing two conserved arginine residues (Arg109/Arg108 and Arg113/Arg112), which reveals a previously unknown key role for these residues. The present study highlights the key role of the aspartate residue whose blockage could be useful in the rational design of inhibitors and the mechanistic differences between both enzymes
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Antiviral agents: structural basis of action and rational design

  • Menéndez-Arias, Luis
  • Gago, Federico
During the last 30 years, significant progress has been made in the development of novel antiviral drugs, mainly crystallizing in the establishment of potent antiretroviral therapies and the approval of drugs inhibiting hepatitis C virus replication. Although major targets of antiviral intervention involve intracellular processes required for the synthesis of viral proteins and nucleic acids, a number of inhibitors blocking virus assembly, budding, maturation, entry or uncoating act on virions or viral capsids. In this review, we focus on the drug discovery process while presenting the currently used methodologies to identify novel antiviral drugs by using a computer-based approach. We provide examples illustrating structure-based antiviral drug development, specifically neuraminidase inhibitors against influenza virus (e.g. oseltamivir and zanamivir) and human immunodeficiency virus type 1 protease inhibitors (i.e. the development of darunavir from early peptidomimetic compounds such as saquinavir). A number of drugs in preclinical development acting against picornaviruses, hepatitis B virus and human immunodeficiency virus and their mechanism of action are presented to show how viral capsids can be exploited as targets of antiviral therapy., Work at CBMSO is supported in part by grants of the Spanish Ministry of Economy and Competitiveness (BIO2010/15542) and the General Directorate for Pharmacy and Medical Products (Ministry of Health, Social Services and Equality) (EC11-025), and an institutional grant from the Fundación Ramón Areces. Continued support to F.G. from the Spanish Comisión Interministerial de Ciencia y Tecnología (SAF2009-13914-C02-02) and Comunidad de Madrid (S-BIO/0214/2006 and S2010-BMD-2457) is gratefully acknowledged., Peer reviewed, Peer Reviewed